Client updates / Excessive Pricing

For the First Time, Israel Competition Authority Enforces Prohibition on Excessive Pricing

28 November 2021 / Irit Brodsky

For the first time, the Israel Competition Authority has opened enforcement proceedings against a monopolist for abuse of its dominant position by charging an unfairly high price. Subject to a hearing, the authority intends to impose a pecuniary sanction of ILS 8 million on MBI Pharma Ltd. and personal sanctions on two officers of the company (of about ILS 600,000 each). The company faces accusations of charging an excessive price for Leadiant, a life-saving drug for CTX patients (an incurable genetic disease), which is marketed by MBI Pharma in Israel.

See full article >

Categories: Antitrust and Competition | Regulation

Search by Practice

Client updates / Excessive Pricing